Although the mean fasting glucose achieved with insulin glargine in the present study was 6.78 mmol/l, and only 32.6% of the patients achieved the target of ≤5.6 mmol/l, the study was only 26 weeks, which may have been insufficient to fully control fasting glucose in those patients who had high baseline values.
The lack of benefit may be related to the relatively late initiation of therapy after stroke (median 14 h) and the modest mean reduction in glucose achieved in the treatment arm (0.57 mmol/l).
The mean glucose level achieved during closed-loop control was 7.8 m M and was within the range associated with the lowest mortality in observational studies [ 5, 36].
The positive control, glucose, achieved a mean biodegradation of 81.2% with a standard deviation of 8.8%, whereas betaine achieved a mean biodegradation of 73.3% with a standard deviation of 9.8%.
The abstracted data was as follows: first author, year of publication, region or country, number of study site, sample size, population, patient age, history of diabetes mellitus, initial glucose level, targeted glucose level, and achieved mean glucose value.
The percentage of subjects achieving mean glucose 3.9 10.0 mmol/L was also similar (70 vs. 71%, P > 0.99).
After 24 h, the insulin algorithm achieved a mean glucose level of 6.53 mmol/L (SD 2.8) [117.5 mg/dL (SD 50)], whereas the standard therapy achieved a mean glucose level of 7.94 mmol/L (SD 3.23) [142.9 mg/dL (58)].
A recent report using a combination of basal insulin with correction insulin achieved a mean glucose value of 160 mg/dl (8.9 mmol/l).
A recent study, in which a combination of basal insulin and correction insulin was used, achieved a mean glucose value of 160 mg/dl (8.9 mmol/l).
This study demonstrated that prandial insulin delivered using a flexible or fixed meal dosing strategy achieved similar mean glucose levels in hospitalized patients, with no difference in the frequency of hypoglycemia or overall patient satisfaction.
